108 related articles for article (PubMed ID: 9065731)
1. KW-2149 (7-N-[2-[gamma-L-glutamylamino]ethyldithioethyl]mitomycin C). A new mitomycin C analogue activated by serum.
Masters JR; Know RJ; Hartley JA; Kelland LR; Hendriks HR; Connors T
Biochem Pharmacol; 1997 Feb; 53(3):279-85. PubMed ID: 9065731
[TBL] [Abstract][Full Text] [Related]
2. KW-2149 (7-N-[2-[gamma-L-glutamylamino]ethyldithioethyl] mitomycin C): DNA interactions and drug uptake following serum activation.
McAdam SR; Knox RJ; Hartley JA; Masters JR
Biochem Pharmacol; 1998 Jun; 55(11):1777-83. PubMed ID: 9714295
[TBL] [Abstract][Full Text] [Related]
3. Circumvention of glutathione-mediated mitomycin C resistance by a novel mitomycin C analogue, KW-2149.
Ishida T; Nishio K; Kurokawa H; Arioka H; Fukumoto H; Fukuoka K; Nomoto T; Yokote H; Hasegawa S; Saijo N
Int J Cancer; 1997 Sep; 72(5):865-70. PubMed ID: 9311606
[TBL] [Abstract][Full Text] [Related]
4. Nonenzymatic reductive activation of 7-N-((2-([2-(gamma-L-glutamylamino)ethyl]dithio)ethyl))mitomycin C by thiol molecules: a novel mitomycin C derivative effective on mitomycin C-resistant tumor cells.
Lee JH; Naito M; Tsuruo T
Cancer Res; 1994 May; 54(9):2398-403. PubMed ID: 8162587
[TBL] [Abstract][Full Text] [Related]
5. 7-N-(2-([2-(gamma-L-glutamylamino)-ethyl]-dithio)-ethyl)-mitomycin C (KW-2149) is more active than mitomycin C on chemonaive and drug-resistant urothelial carcinoma cells.
Rohde D; Raffenberg G; Kaviani S; Wolff J; Jakse G
Urol Res; 1998; 26(4):243-7. PubMed ID: 9759997
[TBL] [Abstract][Full Text] [Related]
6. Modulation of sensitivity to mitomycin C and a dithiol analogue by tempol in non-small-cell lung cancer cell lines under hypoxia.
Bando T; Kasahara K; Shibata K; Numata Y; Heki U; Shirasaki H; Iwasa K; Fujimura M; Matsuda T
J Cancer Res Clin Oncol; 1996; 122(1):21-6. PubMed ID: 8543588
[TBL] [Abstract][Full Text] [Related]
7. Determination of the new anticancer agent KW 2149, 7-N-[2-[2-(gamma-L-glutamylamino)ethyl)dithio)ethyl]mitomycin C, an analogue of mitomycin C.
Pattyn G; van Oosterom AT; de Bruijn EA; Tjaden UR
J Chromatogr; 1991 Mar; 564(1):352-4. PubMed ID: 1860933
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of 7-N-[[2-[[2-(gamma-L-glutamylamino)ethyl]dithio]ethyl]]-mitomycin C.
Morimoto M; Ashizawa T; Ohno H; Azuma M; Kobayashi E; Okabe M; Gomi K; Kono M; Saitoh Y; Kanda Y
Cancer Res; 1991 Jan; 51(1):110-5. PubMed ID: 1988076
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxic activity of 7-N-(2-((2-(-gamma-L-glutamylamino)- ethyl)dithio)ethyl)-mitomycin C and metabolites in cell lines with different resistance patterns.
Dirix LY; Gheuens EE; van der Heyden S; van Oosterom AT; De Bruijn EA
Anticancer Drugs; 1994 Jun; 5(3):343-54. PubMed ID: 7919460
[TBL] [Abstract][Full Text] [Related]
10. Characteristics of the antitumor activity of M-16 and M-18, major metabolites of a new mitomycin C derivative KW-2149, in mice.
Ashizawa T; Okamoto A; Okabe M; Kobayashi S; Arai H; Saito H; Kasai M; Gomi K
Anticancer Drugs; 1995 Dec; 6(6):763-70. PubMed ID: 8845489
[TBL] [Abstract][Full Text] [Related]
11. Effects and systemic uptake of the new mitomycin C analogue KW-2149 in beagle dogs after intravesical administration.
Sorber M; De Bruijn EA; Kockx M; Bultinck J; Van Oosterom AT; Denis L
Urol Res; 1995; 23(3):157-61. PubMed ID: 7483141
[TBL] [Abstract][Full Text] [Related]
12. The influence of hypoxia on the cytotoxicity of concomitant KW-2149 and ionizing irradiation in Chinese hamster fibroblasts.
Egelmeers A; Dirix LY; Lyczek J; De Bruijn EA; Van Oosterom AT; Scalliet P
Anticancer Drugs; 1996 Jul; 7(5):586-90. PubMed ID: 8862727
[TBL] [Abstract][Full Text] [Related]
13. Structural determination of the conjugate of human serum albumin with a mitomycin C derivative, KW-2149, by matrix-assisted laser desorption/ionization mass spectrometry.
Yasuzawa T; Tomer KB
Bioconjug Chem; 1997; 8(3):391-9. PubMed ID: 9177846
[TBL] [Abstract][Full Text] [Related]
14. Induction of protein-DNA complexes in HeLa S3 cells by KW-2149, a new derivative of mitomycin C.
Fujii N; Arai H; Saito H; Kasai M; Nakano H
Cancer Res; 1993 Oct; 53(19):4466-8. PubMed ID: 8402614
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxic potential of monoalkylation products between mitomycins and DNA: studies of decarbamoyl mitomycin C in wild-type and repair-deficient cell lines.
Kim SY; Rockwell S
Oncol Res; 1995; 7(5):39-47. PubMed ID: 8534933
[TBL] [Abstract][Full Text] [Related]
16. Disposition and metabolism of KW-2149, a novel anticancer agent.
Kobayashi S; Ushiki J; Takai K; Okumura S; Kono M; Kasai M; Gomi K; Morimoto M; Ueno H; Hirata T
Cancer Chemother Pharmacol; 1993; 32(2):143-50. PubMed ID: 8485809
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxic potential of monoalkylation products between mitomycins and DNA: studies of decarbamoyl mitomycin C in wild-type and repair-deficient cell lines.
Rockwell S; Kim SY
Oncol Res; 1995; 7(1):39-47. PubMed ID: 7549043
[TBL] [Abstract][Full Text] [Related]
18. Formation of a major DNA adduct of the mitomycin metabolite 2,7-diaminomitosene in EMT6 mouse mammary tumor cells treated with mitomycin C.
Palom Y; Belcourt MF; Kumar GS; Arai H; Kasai M; Sartorelli AC; Rockwell S; Tomasz M
Oncol Res; 1998; 10(10):509-21. PubMed ID: 10338154
[TBL] [Abstract][Full Text] [Related]
19. Bioreductive metabolism of mitomycin C in EMT6 mouse mammary tumor cells: cytotoxic and non-cytotoxic pathways, leading to different types of DNA adducts. The effect of dicumarol.
Palom Y; Belcourt MF; Tang LQ; Mehta SS; Sartorelli AC; Pritsos CA; Pritsos KL; Rockwell S; Tomasz M
Biochem Pharmacol; 2001 Jun; 61(12):1517-29. PubMed ID: 11377381
[TBL] [Abstract][Full Text] [Related]
20. Reduced bone marrow toxicity of KW-2149, a mitomycin C derivative, in mice.
Ashizawa T; Okabe M; Gomi K; Hirata T
Anticancer Drugs; 1993 Apr; 4(2):181-8. PubMed ID: 8490196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
